Baseline Clinical Characteristics of HD and Control Enrolled Patients
| Characteristic | HD | Control | P |
| Age (y) | 39 ± 13 (range, 19–58) | 41 ± 8 (range, 20–72) | NS |
| Male sex | 37/69 (53%) | 35/69 (50%) | NS |
| Weight (kg) | 67.1 ± 12 | 76.5 ± 7 | <0.05 |
| Glycemia at 18F-FDG injection (mg/dL) | 79 ± 7 (range, 61–101) | 83 ± 11 (range, 62–94) | NS |
| Cardiovascular risk profile | |||
| Hypertension | 6/69 (8%) | 15/69 (21%) | <0.01 |
| Tobacco use | 19/69 (27%) | 30/69 (43%) | <0.05 |
| Total cholesterol | 183.7 ± 30 | 188 ± 53 | NS |
| Low-density lipoprotein | 114.5 ± 32 | 120 ± 25 | NS |
| Triglycerides | 121.3 ± 49 | 129.7 ± 57 | NS |
| Creatinine | 0.8 ± 0.1 | 0.85 ± 0.2 | NS |
| Family history of CAD | 7/69 (10%) | 5/69 (7%) | NS |
| Time intervals between PET studies | |||
| PET1–PET2 (d) | 73.7 ± 21 | 99 ± 90 | <0.05 |
| PET2–PET3 (d) | 148 ± 70 | 167 ± 98 | NS |
| PET3–PET4 (d) | 195 ± 92 | 229 ± 100 | NS |
| Overall PET1–PET4 (d) | 427 ± 198 | 448 ± 141 | NS |
| Baseline Ann-Arbor staging | |||
| I stage | 7/69 (10%) | — | — |
| II stage | 42/69 (60%) | — | — |
| III stage | 8/69 (12%) | — | — |
| IV stage | 12/69 (17%) | — | — |
| B symptoms | 10/69 (14%) | — | — |
| Mediastinal radiotherapy | 35/69 (55%) | — | — |
| Total administered doxorubicin dose (mg) | 456.6 ± 103 | — | — |
NS = not statistically significant; CAD = coronary artery disease.
Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as mean ± SD.